Skip to content
drillr.ai
Sign up

01952.HK

Everest Medicines Limited

HKSE · Healthcare · Biotechnology · CN

HKD 27.58
+4.71%
Ask drillr

  • Sep 16, 2026, 23:53 UTC

    China's NMPA Center for Drug Evaluation accepted Everest Medicines' marketing registration application to transfer production of VELSIPITY (etrasimod arginine tablets) from overseas to within China, with priority review granted.

    Source:

  • Aug 20, 2026, 01:46 UTC

    On August 20, 2026, Hong Kong-listed biotech stocks surged broadly, with 3D Medicines rising 55%, Everest Medicines rising 50%, CanSino Biologics rising 45%, and other biotech firms gaining sharply.

    Source:

  • Aug 19, 2026, 00:50 UTC

    Everest Medicines reported interim results for the six months ended June 2026, with revenue of RMB 1.148 billion, up 157.3% year-on-year, and net loss narrowed to RMB 5.944 million from nearly RMB 250 million a year earlier.

    Source:

  • Jul 15, 2026, 01:14 UTC

    JD Health and Everest Medicines signed a strategic cooperation agreement to jointly explore new models for full-cycle services of innovative drugs.

    Source:

  • Jun 8, 2026, 15:35 UTC

    LENZ Therapeutics granted Everest Medicines the rights to develop and commercialize its presbyopia drug VIZZ (LNZ100) in Greater China.

    Source:

  • Jun 8, 2026, 00:55 UTC

    Everest Medicines entered into an Asset Purchase Agreement with Corxel Pharmaceuticals to acquire the rights to develop, manufacture, and commercialize LNZ100 in Greater China.

    Source:

  • Jun 4, 2026, 04:00 UTC

    Everest Medicines entered into an exclusive licensing and collaboration agreement with Travere Therapeutics for civorebrutinib, a BTK inhibitor for rare kidney diseases.

    Source:

  • Jun 2, 2026, 00:00 UTC

    Travere Therapeutics entered into a license and collaboration agreement with Everest Medicines to develop and commercialize civorebrutinib (EVER001) outside China and select East and Southeast Asia.

    Source: